The Food and Drug Administration Friday approved the first generic naloxone nasal spray, an emergency treatment for opioid overdose intended for use in the community. Generic injectable naloxone products have been available for use in health care settings for years. The FDA has previously approved a brand-name naloxone nasal spray and an auto-injector for use by those without medical training. “In addition to this approval of the first generic naloxone nasal spray, moving forward we will prioritize our review of generic drug applications for naloxone,” said Douglas Throckmorton, M.D., deputy center director for regulatory programs at the FDA’s Center for Drug Evaluation and Research.

Related News Articles

Headline
Organizations can apply through July 29 for a portion of $10 million in funding to expand access to medication-assisted treatment for opioid use disorder in…
Headline
The Centers for Disease Control and Prevention yesterday updated its guidance to help clinicians evaluate and test patients with relevant history, signs and…
Headline
AHA Friday urged lawmakers to consider certain changes to the Verifying Accurate Leading-Edge IVCT Development (VALID) Act, legislation that would modify the…
Headline
The Department of Health and Human Services today withdrew a Trump Administration rule that would require the agency to assess periodically each…
#HealthCareInnovation Thursday Blog
How could I have been so unprepared? I held my 3-year-old’s hand tighter than a pediatrician would approve of as together we watched paramedics resuscitate…
Headline
Testifying today at an Occupational Safety and Health Administration hearing, AHA policy staff urged the agency not to finalize its emergency temporary…